Health Care·Health Care Equipment·$23.8B
Dexcom Inc (DXCM) is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes. As a leader in health care equipment, its technology plays a crucial role in managing diabetes, a growing health concern worldwide.
EPS
Earnings per share is a key indicator of profitability and is closely watched by investors.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
63%
Avg EPS Surprise
+0.14%
Avg Stock Reaction
-0.80%
In Q4-2025, Dexcom reported an EPS of $0.68, beating estimates by 4.62%. However, the stock declined by 4.50% the following day, indicating mixed investor sentiment despite the positive earnings surprise.
Management Promises & Guidance
Analysts expect Dexcom to report a solid performance in Q1-2026, with a consensus EPS of $0.47 and revenue of $1.2 billion. The market will be closely watching for any updates on product demand and operational efficiency.
Bull Case
If Dexcom exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products and lead to a positive market reaction.
Bear Case
Conversely, if the company misses EPS estimates or provides weak guidance, it could raise concerns about sales momentum and competitive pressures, leading to a negative response from investors.
EPS
0.47Earnings per share is a key indicator of profitability and is closely watched by investors.
Revenue
1.2BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Dexcom's EPS exceed the consensus estimate of $0.47?
A beat on EPS could indicate strong operational performance and boost investor confidence.
Q2
What are the revenue growth trends in the continuous glucose monitoring segment?
Understanding revenue growth will provide insights into market demand and the company's competitive position.
Why consensus could be wrong
The consensus may underestimate Dexcom's ability to capture market share due to its innovative product pipeline and strong customer loyalty.
Supporting Evidence
Recent product launches have received positive feedback, suggesting potential for higher sales.
The company's historical performance shows a consistent ability to exceed EPS estimates.
Market trends indicate a growing demand for diabetes management solutions.
Key Risk
If revenue growth exceeds $1.3 billion, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Dexcom can maintain its growth trajectory in a competitive landscape.
Bull Confirmed If
An EPS of $0.50 or higher would confirm strong demand and operational efficiency.
Bear Confirmed If
An EPS below $0.42 would raise concerns about sales and market share.
Implied Move
±4.2%
The options market is pricing in a potential move of 4.2% around the earnings announcement, indicating uncertainty among investors.
Cross-company pattern from 30 similar setups.
Prior-quarter beat setup in Health Care
n=30Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.9%, with a raw directional average of +2.3% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Dexcom beats expectations, history suggests a potential average one-day move of +1.67%, confirming strong demand and operational strength.
In-Line / Cautious
If results are in line with expectations, the stock may react cautiously as investors await further guidance.
Miss
If the company misses estimates, history suggests an average one-day move of +0.65%, indicating potential concerns about future growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026